Liquid biopsy for ALK-positive early non-small-cell lung cancer predicts disease relapse.

Liquid biopsy for ALK-positive early non-small-cell lung cancer predicts disease relapse.:

Liquid biopsy for ALK-positive early non-small-cell lung cancer predicts disease relapse.

Future Oncol. 2020 Sep 29;:

Authors: Li J, Dong W, Liu LN, Huang YJ, Xiao MF

Abstract

Background: We aimed to determine whether circulating tumor cells (CTCs) and cell-free DNA (cfDNA) aids in prognosis of relapse-free survival (RFS). Methods: Non-small cell lung cancer patients with ALK mutations were recruited prospectively. CTCs and cfDNA were quantified at different time points. RFS was estimated and correlated. Results: Baseline median CTCs and cfDNA were 16 cells and 57 ng/mL and declined to nine cells and 30 ng/mL, respectively, postsurgery in 150 patients. Interestingly, patients without detectable CTCs postsurgery fared better for RFS. cfDNA monitoring showed deviations within 7 months of surgery that were significant predictors for RFS. Conclusion: Short-term monitoring of CTCs and cfDNA variations shows promise for early risk detection and may aid in better disease control.



PMID: 32988235 [PubMed - as supplied by publisher]